Algernon Pharmaceuticals Inc.

Listing Exchange:

CSE

Status:

Active

Industry:

Life Sciences

Symbol:

AGN

Associated Securities:

Algernon Pharmaceuticals Inc. 27APRIL2023 Rights

CSE Index:

Currency:

Algernon Pharmaceuticals is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.

Algernon Pharmaceuticals Inc. (AGN)

SEDAR Information

Company Info

Address

Suite 1500 - 1055 West Georgia Street

Vancouver, BC V6E4N7

Canada

Phone

604-398-4175

Ext

701

info@algernonpharmaceuticals.com

Website

http://algernonpharmaceuticals.com

Listing date

Monday, February 1, 2016

Transfer Agent

TSX Trust Company

Auditor

Smythe LLP

Capitalization

Issued & Outstanding:

9,653,724

Reserved for Issuance:

4,968,996

News Releases

21/03/2023

Algernon Pharmaceuticals Announces Launch of Rights Offering

02/03/2023

Algernon NeuroScience Appoints Global TBI Expert and Former NFL Neurological Player Care Safety Director Dr. David Brody to Advisory Board

Bulletins

27/03/2023

2023-0337 - New Listing - Algernon Pharmaceuticals Inc. 27APRIL2023 Rights

le 27 mars/March 2023

Bulletins

27/03/2023

2023-0337 - New Listing - Algernon Pharmaceuticals Inc. 27APRIL2023 Rights

le 27 mars/March 2023

01/03/2023

2023-0303 – Stock Split - Algernon Pharmaceuticals Inc. (AGN)

le 1 mars/March 2023

Algernon Pharmaceuticals Inc. has announced a four (4) for one (1) stock split of its issued and outstanding common shares. Each shareholder of record as of the close of business on the record date will receive three (3) additional shares for each share held on such date.

18/11/2021

2021-1131 – Consolidation - Algernon Pharmaceuticals Inc. (AGN)

Le 18 novembre/November 2021

Algernon Pharmaceuticals Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every one hundred (100) pre-consolidated common shares.

As a result, the outstanding shares of the company will be reduced to approximately 1,678,809 common shares.

The name and symbol will not change.

19/01/2021

2021-0122 - Expiry – Algernon Pharmaceuticals Inc. – Warrants (AGN.WT)

le 19 janvier/January 2021

Further to Bulletin 2020-1240, Algernon Pharmaceuticals Inc. warrants will expire on January 21, 2021.

Settlement Terms: All trades January 19^th and 20^th will settle for cash next day. Trades on January 21 will be for cash same day.

The warrants will be halted at noon and delisted at market close January 21, 2021.

14/02/2019

2019-0226 – Name and Symbol Change - Breathtec Biomedical Inc. (BTH)

Le 14 février/February 2019

Breathtec Biomedical Inc. (BTH) has announced a name and symbol change to Algernon Pharmaceuticals Inc. (AGN).

Shares will begin trading under the new name and symbol on February 19, 2019.

16/10/2018

2018-1021 – Consolidation - Breathtec BioMedical Inc. (BTH)

Le 16 octobre/October 2018

Breathtec BioMedical Inc. has announced a consolidation of its issued and outstanding share capital on the basis of one (1) post-consolidation share for each two (2) pre-consolidation common shares.

As a result, the outstanding shares of the company will be reduced to approximately 28,682,012.

The shares will begin trading on a consolidated basis and with a new CUSIP number on October 17, 2018.

The name and symbol will not change.

29/01/2016

2016-0125 - New Listing – Breathtec BioMedical Inc. (BTH)

Trading to commence Monday February 1, 2016 under the symbol BTH.

CSE Filings

File	Type	Date
Algernon Pharmaceuticals - Notice of Rights Offering	Other	21/03/2023
Algernon Pharmaceuticals - Rights Offering Circular	Other	21/03/2023
Algernon Pharmaceuticals - Confirmation of Mailing re forward stock split	Confirmation of Mailing	14/03/2023
Algernon Pharmaceuticals - Form 7 Monthly Report (February 2023)	Monthly Progress Report	07/03/2023
Algernon Pharmaceuticals - Notice of Record Date for Stock Split	Proposed Stock Consolidation	28/02/2023
Algernon Pharmaceuticals - Notice of Stock Split	Proposed Stock Consolidation	28/02/2023
Algernon Pharmaceuticals - Form 7 Monthly Report (January 2023)	Monthly Progress Report	07/02/2023
Algernon Pharmaceuticals - CFO certificate for quarter ended November 30, 2022	Other	30/01/2023
Algernon Pharmaceuticals - CEO certificate for quarter ended November 30, 2022	Other	30/01/2023

1
2
3
4
5
6
7
8
9
…
next ›
last »

Algernon Pharmaceuticals Inc.

You are here

Algernon Pharmaceuticals Inc. (AGN)

SEDAR Information

Company Info

Capitalization

News Releases

Algernon Pharmaceuticals Announces Launch of Rights Offering

Algernon NeuroScience Appoints Global TBI Expert and Former NFL Neurological Player Care Safety Director Dr. David Brody to Advisory Board

Bulletins

2023-0337 - New Listing - Algernon Pharmaceuticals Inc. 27APRIL2023 Rights

CSE Filings

Algernon Pharmaceuticals - Notice of Rights Offering

Algernon Pharmaceuticals - Rights Offering Circular

Algernon Pharmaceuticals - Confirmation of Mailing re forward stock split

Algernon Pharmaceuticals - Form 7 Monthly Report (February 2023)

Algernon Pharmaceuticals - Notice of Record Date for Stock Split

Latest CSE News

Upcoming Events

Benzinga Cannabis Capital Conference

Connect with us:

You are here

Algernon Pharmaceuticals Inc.

You are here

Algernon Pharmaceuticals Inc. (AGN)

SEDAR Information

Search form

Company Info

Capitalization

News Releases

News Releases

Bulletins

Bulletins

CSE Filings

CSE Filings

Latest CSE News

Upcoming Events

Connect with us: